Gotham Asset Management LLC Has $1.15 Million Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Gotham Asset Management LLC raised its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 4.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 12,905 shares of the medical equipment provider’s stock after buying an additional 596 shares during the period. Gotham Asset Management LLC’s holdings in Lantheus were worth $1,154,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in LNTH. Farallon Capital Management LLC lifted its holdings in Lantheus by 79.9% in the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock valued at $475,590,000 after buying an additional 2,361,000 shares during the period. T. Rowe Price Investment Management Inc. lifted its stake in shares of Lantheus by 40.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock valued at $135,025,000 after purchasing an additional 435,445 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Lantheus by 2.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider’s stock valued at $120,510,000 after purchasing an additional 30,891 shares during the period. Swedbank AB lifted its stake in shares of Lantheus by 53.3% in the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock valued at $99,054,000 after purchasing an additional 385,000 shares during the period. Finally, Northern Trust Corp lifted its stake in shares of Lantheus by 11.7% in the 4th quarter. Northern Trust Corp now owns 916,384 shares of the medical equipment provider’s stock valued at $81,980,000 after purchasing an additional 96,275 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LNTH has been the topic of a number of analyst reports. B. Riley cut their price target on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. Truist Financial cut their price target on Lantheus from $127.00 to $117.00 and set a “buy” rating on the stock in a research note on Thursday, May 8th. Finally, StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Lantheus presently has a consensus rating of “Buy” and a consensus target price of $132.67.

Lantheus Stock Up 1.8%

LNTH opened at $81.24 on Friday. Lantheus Holdings, Inc. has a 12 month low of $75.00 and a 12 month high of $126.89. The company has a fifty day simple moving average of $97.11 and a 200 day simple moving average of $93.20. The stock has a market cap of $5.62 billion, a P/E ratio of 13.52 and a beta of 0.23.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. During the same quarter in the prior year, the company earned $1.69 EPS. Lantheus’s quarterly revenue was up .8% on a year-over-year basis. On average, equities research analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insider Activity at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. This represents a 10.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. This trade represents a 8.07% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 63,109 shares of company stock worth $6,016,046 in the last quarter. Corporate insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.